T cells that result from antiviral therapy or IL-2 therapy The possibility of treating AIDS by gene therapy stems from the consideration that HIV infection, like any viral are derived from the expansion of existing CD4 + cells, rather than from the emergence of new CD4
+ cells from infection, is a true genetic disorder, resulting from the acquisition of new genetic material via an infectious prothe thymus. 1 Thus, once an element of the T cell repertoire has been lost through HIV infection, it is unlikely cess. In addition, infection by a retrovirus, such as HIV, involves the integration by viral genes into chromosomal to be replaced by a stem cell compartment. These findings, from an immunological perspective, point to the DNA to become a stable, inheritable feature of the cell genome. The lysogenic nature of retroviral infection renimportance of early intervention and suggest that genetic modification of peripheral CD4 + cells, rather than that of ders HIV eradication virtually impossible by conventional antiviral drugs such as reverse transcriptase and the CD34 + population, is a rational therapeutic strategy for HIV-infected individuals. A stem cell compartment protease inhibitors, despite recent progress in pharmacological treatment. The major limitations of these and should be considered instead, when pursuing genetic modification of dendritic cells, monocytes/macrophages other drugs lie in selective toxicity and viral resistance. Both features pertain to the strict stereospecific discrimiand microglial cells. All these elements, which share a common committed progenitor, are responsible for nation that a small effector antiviral molecule has to operate on the tridimensional structure of a viral target prospreading the infection to blood, lymphoid organs and the CNS. Transduction of the above cells as individual tein. The genetic approach has all the properties required to be more powerful as the expression of a therapeutic elements appears an insurmountable task, due to their widespread distribution within the organism and their gene can provide the cell with a new effector function which is macromolecular in nature. It ensures that in diverse pattern of recirculation and homing. Suitable vectors for genetic treatment of mature, antisome cases, target recognition can take place by virtue of primary or secondary structure complementarity. Gene gen-specific, CD4 + cells or cells of the monocyte-macrophage lineage and progenitors thereof, will have to be therapy (GT) of AIDS, to be efficacious, has to achieve a significant antiviral effect at the site of viral replication.
capable of chromosomal integration in the absence of cell mitosis. These vectors, in addition, should be endowed It should as well restore/maintain the immune function by preserving the T cell repertoire, whose failure leads with a greater gene transfer efficiency than conventional Moloney prototype vectors. Lentiviral vectors based on to fatal opportunistic infections. In synthesis, GT of AIDS should work by preventing de novo infection of suscep-HIV-1 and HIV-2 have recently been produced and shown to be efficient in transducing resting blood cells tible cells and by suppressing ongoing replication in chronically infected cells. To achieve these goals, two and neuronal cells. 2 Although virus titers are presently low, mainly due to lack of suitable packaging cell major requirements have to be met. Firstly, the identification of cells or tissues that need to be genetically lines for stable, in trans production of HIV structural components, these vectors have a number of potential treated and secondly, the availability of suitable vector systems and therapeutic genes. If the concept of preadvantages. venting HIV infection includes blocking routes of viral entry and spreading to the body, one should be aware of
• The selective tropism for HIV susceptible cells, dictated by the gp120 stereospecific recognition of CD4 and the monocyte-macrophage lineage cells that inhabit mucosal tissues. These cells are the site of initial HIV repcoreceptor molecules.
• The susceptibility of HIV particles to be pseudotyped lication when infection is acquired by sexual contact. A real prophylactic application of GT is presently inconby other viral envelopes, which results in tropism expansion to include CD4 − cells and stem cells in ceivable if a prior demonstration of the therapeutic efficacy of this approach is not obtained in infected individparticular.
• The inducibility of the LTR by the same signals that uals. Already infected individuals would benefit from a genetic treatment that prevents viral replication in the activate wild-type virus.
• The potential for multiple gene expression associated main target cell, the CD4 + T lymphocytes, whose exhaustion eventually leads to the immunodeficiency syndrome.
with the mechanisms of transactivation, alternative splicing and nucleus-cytoplasm transport typical of Adoptive transfer of genetically modified syngeneic lymphocytes in HIV-discordant identical twins has shown lentiviruses.
• The likely production of homologous interference with repertoire lost in the course of HIV infection. This treatment, especially if associated with antivirals, can partiwild-type HIV-1.
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• The possibility of provirus deletion following homolocularly benefit individuals in the early phase of viral infection. gous recombination or site-directed DNA integration of the vector driven by a recombinase system. 4 Among the many isues of GT of AIDS that remain open, that of viral resistance has not been properly addressed, not even by in vitro studies. A relevant clinical Meanwhile, as lentiviral or AAV vectors are further and experimental finding is the observation that genetituned up, GT of AIDS will have to depend on ex vivo cally marked CD8 cells reinfused in AIDS patients can transduction of relevant cells with a new generation of undergo immunoclearance, due to the expression of a more efficient Moloney vectors. Therapeutic strategies so foreign gene (TK, hygro) in association with MHC I molfar adopted include transduction of peripheral lymphoecules. 6 This points to the use of vectors carrying genes cytes and bone marrow cells with a number of therafor positive selection different from those of prokaryotic peutic genes able to suppress HIV infection. The supor viral origin. A note of confidence has come from pressive mechanisms involve prevention of HIV Nabel's clinical trial, demonstrating that GT of AIDS can integration; inhibition of proviral gene expression to be safely approached in human beings, with some eviindefinitely prolong latency; and activation of suicide dence of effectiveness. 7 Further adoption of gene transfer genes in virally infected cells. Suppression of HIV repliin vivo is clearly warranted and would mainly serve for cation can be obtained through intracellular production a better appraisal of toxicity and safety issues as well as of therapeutic RNA and protein molecules, some of for a definition of the more active viral vectors and which are simultaneously expressed by the same vector.
therapeutic genes. These molecules include TAR and RRE decoys, antisense
After an enthusiastic acceptance of GT as the likely and catalytic RNAs, peptides with transdominant negapanacea for disorders such as cancer, genetic and infective effect, intrabodies and prodrug activating enzymes.
tious diseases, a certain skepticism is now pervading the With respect to therapeutic peptides, therapeutic RNA scene. This stems from the consideration of how many has the advantage of being free of immunogenic properpatients do really benefit from genetic treatment. Moreties. Therapeutic RNA, moreover, can be produced in the over, old and new biosafety and ethical issues are the context of a selfish (intron) or physiological molecule subject of continuous debate by the scientific community. (tRNA or snRNA); can have enzymatic activity; can act
The present risk of a GT backlash can only be counteras a decoy; and localize into selected intracellular comacted by solid, basic research studies concerning vector partments. Simultaneous expression of anti-HIV genes design, homologous gene substitution and regulated-(decoy and ribozyme) has been shown to synergyze in tethered expression of therapeutic genes. producing an antiviral response. 
